Compare MGNX & MFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGNX | MFIN |
|---|---|---|
| Founded | 2000 | 1995 |
| Country | United States | United States |
| Employees | N/A | 179 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.6M | 232.1M |
| IPO Year | 2013 | N/A |
| Metric | MGNX | MFIN |
|---|---|---|
| Price | $4.20 | $9.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $5.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.3M | 54.4K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 5.18% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.19 | $0.02 |
| P/E Ratio | ★ N/A | $6.21 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $7.85 |
| 52 Week High | $4.64 | $11.00 |
| Indicator | MGNX | MFIN |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 51.36 |
| Support Level | $1.49 | $9.15 |
| Resistance Level | $4.64 | $9.87 |
| Average True Range (ATR) | 0.30 | 0.31 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 60.50 | 46.15 |
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.